학술논문

Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster.
Document Type
Editorial
Source
FEBS Journal. Oct2016, Vol. 283 Issue 19, p3508-3522. 15p.
Subject
*ALZHEIMER'S disease risk factors
*LYSOZYMES
*IMMUNOGENETICS
*AMYLOID beta-protein
*GENETIC polymorphisms
*DROSOPHILA as laboratory animals
Language
ISSN
1742-464X
Abstract
Genetic polymorphisms of immune genes that associate with higher risk to develop Alzheimer's disease ( AD) have led to an increased research interest on the involvement of the immune system in AD pathogenesis. A link between amyloid pathology and immune gene expression was suggested in a genome-wide gene expression study of transgenic amyloid mouse models. In this study, the gene expression of lysozyme, a major player in the innate immune system, was found to be increased in a comparable pattern as the amyloid pathology developed in transgenic mouse models of AD. A similar pattern was seen at protein levels of lysozyme in human AD brain and CSF, but this lysozyme pattern was not seen in a tau transgenic mouse model. Lysozyme was demonstrated to be beneficial for different Drosophila melanogaster models of AD. In flies that expressed Aβ1-42 or Aβ PP together with BACE1 in the eyes, the rough eye phenotype indicative of toxicity was completely rescued by coexpression of lysozyme. In Drosophila flies bearing the Aβ1-42 variant with the Arctic gene mutation, lysozyme increased the fly survival and decreased locomotor dysfunction dose dependently. An interaction between lysozyme and Aβ1-42 in the Drosophila eye was discovered. We propose that the increased levels of lysozyme, seen in mouse models of AD and in human AD cases, were triggered by Aβ1-42 and caused a beneficial effect by binding of lysozyme to toxic species of Aβ1-42, which prevented these from exerting their toxic effects. These results emphasize the possibility of lysozyme as biomarker and therapeutic target for AD. [ABSTRACT FROM AUTHOR]